A Phase 1 Study of Lenalidomide Maintenance Following Allogeneic Hematopoietic Cell Transplantation in Patients With Select High Risk Hematological Malignancies

Trial Profile

A Phase 1 Study of Lenalidomide Maintenance Following Allogeneic Hematopoietic Cell Transplantation in Patients With Select High Risk Hematological Malignancies

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Dec 2016

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Acute myeloid leukaemia; B cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia; Follicular lymphoma; Hairy cell leukaemia; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Sezary syndrome; T cell lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 26 Mar 2013 Planned number of patients changed from 90 to 60 as reported by ClinicalTrials.gov.
    • 26 Mar 2013 Planned end date changed from 1 Nov 2013 to 1 Dec 2016 as reported by ClinicalTrials.gov.
    • 15 Nov 2012 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top